About Earli
Earli is a company based in San Francisco (United States) founded in 2018 by Sam Gambhir, David Suhy, and Cyriac Roeding. It operates as a HealthTech. Earli has raised $40 million across 2 funding rounds from investors including Accenture, Khosla Ventures and Perceptive Advisors. The company has 38 employees as of December 31, 2022. Earli offers products and services including Synthetic Biomarkers and Programmable Genetic Constructs. Earli operates in a competitive market with competitors including GRAIL, Color, Delfi Diagnostics, RainDance and Foresight Diagnostics, among others.
- Headquarter San Francisco, United States
- Employees 38 as on 31 Dec, 2022
- Founders Sam Gambhir, David Suhy, Cyriac Roeding
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Earli Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$40 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Accenture
& 9 more
-
Employee Count
38
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Earli
Earli offers a comprehensive portfolio of products and services, including Synthetic Biomarkers and Programmable Genetic Constructs.
Synthetic biomarkers are used for early cancer detection.
Genetic constructs are designed to target cancer cells.
People of Earli
Unlock access to complete
Unlock access to complete
Funding Insights of Earli
Earli has successfully raised a total of $40M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Earli
Earli has secured backing from 10 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Accenture, Khosla Ventures and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Earli
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Earli
Investment portfolio details for Earli
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Earli
Detailed financials for Earli
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Earli Comparisons
Peer comparison for Earli
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Earli
Earli operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Delfi Diagnostics, RainDance and Foresight Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Minimally invasive liquid biopsy tests for cancer detection are developed.
|
Detailed competitors of Earli
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Earli
Complete news archive for Earli
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Earli
Earli was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Earli is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cyriac Roeding is the current CEO of Earli. They have also founded this company.
Earli is a funded company, having raised a total of $40M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Earli is 38.
Earli is engaged in developing innovative solutions for early cancer detection and therapy. Programmable genetic constructs are created to activate only in cancer cells, forcing them to produce therapies that lead to self-destruction. Synthetic biomarkers are utilized to identify hidden cancer at its earliest stages. The company operates within the biotechnology sector, addressing critical challenges in cancer diagnostics and treatment. Partnerships with organizations like Accenture are established to advance their mission. Recognition as a global innovator by the World Economic Forum is received, highlighting their impact in the healthcare industry.
Earli's top competitors include GRAIL, UDX and Delfi Diagnostics.
Earli offers Synthetic Biomarkers and Programmable Genetic Constructs.
Earli has 10 investors. Key investors include Accenture, Khosla Ventures, Perceptive Advisors, Casdin Capital, and Andreessen Horowitz.